LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1838

Search options

  1. Article ; Online: Anti-inflammatory effect and component analysis of Chaihu Qingwen granules.

    Zhou, Ying / Li, Qing-Xian / Liao, Zheng-Zheng / Liu, Yang / Ouyang, Ying / Jiang, Wen-Jing / Tang, Meng-Ting / Hu, Jin-Fang / Zhang, Wei

    Journal of ethnopharmacology

    2023  Volume 317, Page(s) 116763

    Abstract: ... acute lung injury has a quick start and severe symptoms which can harm patients physically. Chaihu Qingwen granules ... group, the ibuprofen group, the Lianhua Qingwen capsule group and the CHQW group (2, 4 and 8 g/kg ...

    Abstract Ethnopharmacological relevance: As prevalent acute respiratory condition in clinical practice, acute lung injury has a quick start and severe symptoms which can harm patients physically. Chaihu Qingwen granules (CHQW) is a classic formula for the treatment of respiratory diseases. Clinical observation shows that CHQW has good efficacy in treating colds, coughs, and fevers.
    Aim of the study: The aim of this study was to investigate the anti-inflammatory effect of CHQW on lipopolysaccharide (LPS)-induced acute lung injury (ALI) model in rats and to explore its potential mechanism, as well as to clarify its substance composition.
    Materials and methods: Male SD rats were randomly divided into the blank group, the model group, the ibuprofen group, the Lianhua Qingwen capsule group and the CHQW group (2, 4 and 8 g/kg, respectively). The LPS-induced acute lung injury (ALI) model in rats was established after pre-administration. The histopathological changes in the lung and the levels of inflammatory factors in bronchoalveolar lavage fluid (BALF) and serum of ALI rats were observed. The inflammation-related proteins toll-like receptor 4 (TLR4), inhibitory kappa B alpha (IκBα), phospho-IκBα (p-IκBα), nuclear-factor-kappa B (NF-κB), and NLR family pyrin domain containing 3(NLRP3) expression levels were measured by western blotting analysis and immunohistochemical analysis. The chemical composition of CHQW was identified by liquid chromatography-quadrupole-time of flight-mass spectrometry (LC-Q-TOF-MS).
    Results: CHQW significantly ameliorated lung tissue pathological injury in LPS-induced ALI rats and decreased the release of inflammatory cytokines (interleukin-1β, interleukin-17 and tumor necrosis factor-α) in BALF and serum. In addition, CHQW decreased the expression of TLR4, p-IκBα and NF-κB proteins, increased the level of IκBα, regulated the TLR4/NF-κB signaling pathway, and inhibited the activation of NLRP3. The chemical components of CHQW were analyzed by LC-Q-TOF-MS, and a total of 48 components were identified by combining information from the literature, mainly flavonoids, organic acids, lignans, iridoids and phenylethanoid glycosides.
    Conclusion: The results of this study showed that the pretreatment of CHQW had a strong protective effect on LPS-induced ALI in rats, reducing lung tissue lesions and decreasing inflammatory cytokines released in BALF and serum. The protective mechanism of CHQW may be related to the inhibition of the TLR4/NF-κB signaling pathway and NLRP3 activation. The main active ingredients of CHQW are flavonoids, organic acids, lignans, iridoids and phenylethanoid glycosides.
    MeSH term(s) Rats ; Male ; Animals ; NF-kappa B/metabolism ; Toll-Like Receptor 4/metabolism ; NF-KappaB Inhibitor alpha ; NLR Family, Pyrin Domain-Containing 3 Protein ; Lipopolysaccharides/pharmacology ; Rats, Sprague-Dawley ; Lung ; Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Acute Lung Injury/metabolism ; Cytokines/metabolism ; Flavonoids/pharmacology ; Flavonoids/therapeutic use ; Anti-Inflammatory Agents/adverse effects ; Glycosides/pharmacology
    Chemical Substances NF-kappa B ; Toll-Like Receptor 4 ; NF-KappaB Inhibitor alpha (139874-52-5) ; NLR Family, Pyrin Domain-Containing 3 Protein ; Lipopolysaccharides ; Cytokines ; Flavonoids ; Anti-Inflammatory Agents ; Glycosides
    Language English
    Publishing date 2023-06-12
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2023.116763
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Impact of Lianhua Qingwen on viral shedding in omicron mild/asymtomatic patients: a real-world study.

    Gai, Xiaoyan / Yan, Changjian / Wu, Chaoling / Duan, Zhonghui / Fan, Jiarun / Yuan, Shengren / Yang, Ping / Bao, Fang / Jing, Hongmei / Cai, Chao / Ma, Yingmin / Zhang, Weilong / Sun, Yongchang

    Frontiers in medicine

    2024  Volume 11, Page(s) 1357299

    Abstract: Background: Lianhuaqingwen (LHQW), a traditional Chinese medicine comprised of 13 herbal extracts renowned for their robust heat-clearing and detoxifying properties, has gained widespread utilization in China but has yet to garner similar recognition ... ...

    Abstract Background: Lianhuaqingwen (LHQW), a traditional Chinese medicine comprised of 13 herbal extracts renowned for their robust heat-clearing and detoxifying properties, has gained widespread utilization in China but has yet to garner similar recognition abroad. It is believed to exhibit efficacy in ameliorating symptoms in individuals afflicted with coronavirus disease 2019 (COVID-19). However, the precise impact of LHQW on viral shedding (VS), particularly in the context of mild or asymptomatic infections caused by the Omicron BF.4/5 or BF.7 variants of COVID-19, remained inadequately elucidated. Consequently, a real-world study was conducted, involving patients diagnosed with COVID-19, with the primary objective of ascertaining the effectiveness of LHQW in this specific clinical context.
    Methods: We conducted an investigation on Omicron-infected patients through a single-center, propensity score-matched real-world study conducted at Xiaotangshan Fangcang Hospital from May to November 2022. A total of 3,368 COVID-19 patients were enrolled in the study, all of whom presented mild or asymptomatic infections caused by either BF.4/5 or BF.7 strains of the virus. Demographic and clinical data were systematically collected from medical records. Patients were allocated to receive treatment with LHQW (designated as the treatment group) or received no LHQW treatment (designated as the not-treated/no-treatment group). Viral load was quantified utilizing quantitative real-time PCR (qPCR), and the duration of VS was defined as the time interval between the initial negative test result and the date of COVID-19 diagnosis or symptom onset.
    Results: The study encompassed a cohort of 3,368 patients, and following propensity score matching, a subset of 296 patients was meticulously chosen for subsequent analysis. Notably, baseline characteristics exhibited disparities between the treatment and not-treated/no-treatment groups. However, post-matching, these characteristics achieved a commendable level of comparability. Our findings unequivocally demonstrated that there existed no statistically significant disparity in VS. This holds true when comparing patients subjected to LHQW treatment against those not administered LHQW, as well as when contrasting individuals presenting asymptomatic and mild COVID-19 manifestations.
    Conclusion: No statistically significant difference in VS was observed between patients who underwent LHQW treatment and those who did not. Additional investigations are imperative to provide a comprehensive assessment of LHQW's efficacy, particularly in patients afflicted with severe COVID-19 or those infected with viral strains distinct from BF.4/5 or BF.7.
    Language English
    Publishing date 2024-03-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2024.1357299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs.

    Chen, Yuanyuan / Zhang, Cheng / Wang, Ning / Feng, Yibin

    Chinese journal of natural medicines

    2023  Volume 21, Issue 5, Page(s) 383–400

    Abstract: ... have been used to relieve the symptoms, with limited therapeutic effect. In contrast, Lianhua Qingwen ... the main pharmacological actions of Lianhua Qingwen Capsule for managing COVID-19; 2) verify the bioactive ... ingredients and pharmacological actions of Lianhua Qingwen Capsule by network analysis; 3) investigate ...

    Abstract The COVID-19 pandemic has resulted in excess deaths worldwide. Conventional antiviral medicines have been used to relieve the symptoms, with limited therapeutic effect. In contrast, Lianhua Qingwen Capsule is reported to exert remarkable anti-COVID-19 effect. The current review aims to: 1) uncover the main pharmacological actions of Lianhua Qingwen Capsule for managing COVID-19; 2) verify the bioactive ingredients and pharmacological actions of Lianhua Qingwen Capsule by network analysis; 3) investigate the compatibility effect of major botanical drug pairs in Lianhua Qingwen Capsule; and 4) clarify the clinical evidence and safety of the combined therapy of Lianhua Qingwen Capsule and conventional drugs. Numerous bioactive ingredients in Lianhu Qingwen, such as quercetin, naringenin, β-sitosterol, luteolin, and stigmasterol, were identified to target host cytokines, and to regulate the immune defence in response to COVID-19. Genes including androgen receptor (AR), myeloperoxidase (MPO), epidermal growth factor receptor (EGFR), insulin (INS), and aryl hydrocarbon receptor (AHR) were found to be significantly involved in the pharmacological actions of Lianhua Qingwen Capsule against COVID-19. Four botanical drug pairs in Lianhua Qingwen Capsule were shown to have synergistic effect for the treatment of COVID-19. Clinical studies demonstrated the medicinal effect of the combined use of Lianhua Qingwen Capsule and conventional drugs against COVID-19. In conclusion, the four main pharmacological mechanisms of Lianhua Qingwen Capsule for managing COVID-19 are revealed. Therapeutic effect has been noted against COVID-19 in Lianhua Qingwen Capsule.
    MeSH term(s) Humans ; COVID-19 ; Pandemics ; Drugs, Chinese Herbal/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19 Drug Treatment
    Chemical Substances Drugs, Chinese Herbal ; Antiviral Agents
    Language English
    Publishing date 2023-05-26
    Publishing country China
    Document type Review ; Journal Article
    ZDB-ID 2192577-X
    ISSN 1875-5364 ; 2095-6975 ; 1672-3651
    ISSN (online) 1875-5364
    ISSN 2095-6975 ; 1672-3651
    DOI 10.1016/S1875-5364(23)60455-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Effectiveness and Safety of Lianhua Qingwen Capsules for COVID-19: A Propensity-Score Matched Cohort Study.

    Lu, Yun / Zhang, Meng / Yang, Qing-Qing / Li, Wen-Jing / Yang, Kun / Hu, Wen / Gao, Su-Yu / Jiang, Qiao-Li / Lin, Li-Kai / Cheng, Hong / Sun, Feng

    Evidence-based complementary and alternative medicine : eCAM

    2023  Volume 2023, Page(s) 6028554

    Abstract: As a traditional Chinese medicine, Lianhua Qingwen capsules have been widely used to treat ... with Lianhua Qingwen capsules and the clinical outcomes of hospitalized patients with COVID-19 ... collected between December 19, 2019 and April 26, 2020. Based on whether Lianhua Qingwen capsules were used ...

    Abstract As a traditional Chinese medicine, Lianhua Qingwen capsules have been widely used to treat Coronavirus Disease 2019 (COVID-19). This study was aimed to demonstrate the association between treatment with Lianhua Qingwen capsules and the clinical outcomes of hospitalized patients with COVID-19. This retrospective study was conducted at four hospitals in Central China. Data of hospitalized COVID-19 patients were collected between December 19, 2019 and April 26, 2020. Based on whether Lianhua Qingwen capsules were used, patients were classified into Lianhua Qingwen and non-Lianhua Qingwen (control) groups. To control for confounding factors, we used conditional logistic regression in a propensity-score matched (PSM) cohort (1 : 1 balanced), as well as logistic regression without matching as sensitivity analysis. A total of 4918 patients were included, 2760 of whom received Lianhua Qingwen capsules and 2158 of whom did not. In the PSM model, after adjusting for confounders, the in-hospital mortality was similar between the Lianhua Qingwen group and the control group (6.8% vs. 3.3%, adjusted OR, 0.66 [95% CI, 0.38-1.15],
    Language English
    Publishing date 2023-02-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2171158-6
    ISSN 1741-4288 ; 1741-427X
    ISSN (online) 1741-4288
    ISSN 1741-427X
    DOI 10.1155/2023/6028554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Lianhua Qingwen protects LPS-induced acute lung injury by promoting M2 macrophage infiltration.

    Li, Shanshan / Feng, Tianyue / Zhang, Yingwen / Shi, Qiqi / Wang, Wanqiao / Ren, Jingyu / Shen, Gangyi / Gu, Haihui / Luo, Chengjuan / Li, Yanxin

    Journal of ethnopharmacology

    2023  Volume 320, Page(s) 117467

    Abstract: Ethnopharmacological relevance: Traditional Chinese medicine Lianhua Qingwen (LHQW) was used ...

    Abstract Ethnopharmacological relevance: Traditional Chinese medicine Lianhua Qingwen (LHQW) was used to treat regular seasonal influenza. In recent years, LHQW exerts significant therapeutic effects in treating influenza and Coronavirus Disease 2019 (COVID-19). However, the potential mechanisms are not yet understood and need further study.
    Aim of study: This study aims to look into the influence of LHQW on lung inflammation and macrophage phenotype, and to clarify the connection between macrophage plasticity and LHQW.
    Methods: The cell viability, marker expression, response to LPS stimulation, and phagocytosis of Raw264.7 were detected after LHQW treatment. In an LPS-induced acute lung injury (ALI) mouse model, the alleviating effect of LHQW on lung injury was investigated. The total macrophages and M2 macrophages in mice lungs and the peripheral blood monocytes after LHQW treatment were detected. The cell viability and polarization of peripheral blood macrophages treated with LHQW were detected.
    Results: Here, we demonstrate that LHQW protects LPS-induced ALI by promoting M2 macrophage infiltration. LHQW treatment inhibited the inflammatory response and pro-inflammatory phenotype of Raw264.7 macrophages. High concentrations of LHQW promoted the phagocytic capacity of Raw264.7 macrophages. In an ALI mouse model, LHQW alleviated lung injury and no significant hepatotoxicity was observed. By Immunohistochemistry (IHC) analysis, LHQW increased the infiltration of macrophages, mainly M2 macrophages. Consistent with Raw264.7, LHQW also decreased the expression of M1 markers in peripheral blood macrophages. In addition, LHQW blood plasma promoted the M2-type polarization of peripheral blood macrophages.
    Conclusions: Taken together, our data demonstrate that LHQW reduces the inflammatory response and ameliorates acute lung injury by promoting anti-inflammatory polarization of macrophages.
    MeSH term(s) Mice ; Animals ; Humans ; Lipopolysaccharides/toxicity ; Lipopolysaccharides/metabolism ; Influenza, Human ; Macrophages ; Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Acute Lung Injury/prevention & control ; Pneumonia/metabolism ; Disease Models, Animal ; Lung
    Chemical Substances Lipopolysaccharides
    Language English
    Publishing date 2023-11-18
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2023.117467
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Network Pharmacology and Experimental Validation of Qingwen Baidu Decoction Therapeutic Potential in COVID-19-related Lung Injury.

    Yang, Ju / Zhang, Zhao / Liu, Honghong / Wang, Jiawei / Xie, Shuying / Li, Pengyan / Wen, Jianxia / Wei, Shizhang / Li, Ruisheng / Ma, Xiao / Zhao, Yanling

    Combinatorial chemistry & high throughput screening

    2023  

    Abstract: ... due to its high infection and serious outcomes resulting from acute lung injury. Qingwen Baidu ...

    Abstract Background and purpose: Coronavirus disease 2019 (COVID-19) is a lifethreatening disease worldwide due to its high infection and serious outcomes resulting from acute lung injury. Qingwen Baidu decoction (QBD), a well-known herbal prescription, has shown significant efficacy in patients with Coronavirus disease 2019. Hence, this study aims to uncover the molecular mechanism of QBD in treating COVID-19-related lung injury.
    Methods: Traditional Chinese Medicine Systems Pharmacology database (TCMSP), DrugBanks database, and Chinese Knowledge Infrastructure Project (CNKI) were used to retrieve the active ingredients of QBD. Drug and disease targets were collected using UniProt and Online Mendelian Inheritance in Man databases (OMIM). The core targets of QBD for pneumonia were analyzed by the Protein-Protein Interaction Network (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) to reveal the underlying molecular mechanisms. The analysis of key targets using molecular docking and animal experiments was also validated.
    Results: A compound-direct-acting target network mainly containing 171 compounds and 110 corresponding direct targets was constructed. The key targets included STAT3, c-JUN, TNF-α, MAPK3, MAPK1, FOS, PPARG, MAPK8, IFNG, NFκB1, etc. Moreover, 117 signaling pathways mainly involved in cytokine storm, inflammatory response, immune stress, oxidative stress and glucose metabolism were found by KEGG. The molecular docking results showed that the quercetin, alanine, and kaempferol in QBD demonstrated the strongest affinity to STAT3, c- JUN, and TNF-α. Experimental results displayed that QBD could effectively reduce the pathological damage to lung tissue by LPS and significantly alleviate the expression levels of the three key targets, thus playing a potential therapeutic role in COVID-19.
    Conclusion: QBD might be a promising therapeutic agent for COVID-19 via ameliorating STAT3-related signals.
    Language English
    Publishing date 2023-11-10
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2064785-2
    ISSN 1875-5402 ; 1386-2073
    ISSN (online) 1875-5402
    ISSN 1386-2073
    DOI 10.2174/0113862073236899230919062725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study.

    Xu, Xiangru / Wu, Hongze / Jin, Guoqiang / Huang, Jihan / Li, Jinhua / Zhou, Jing / Cao, Min / Sun, Ding / Zhang, Wen / Peng, Wei / Pu, Yuting / Chen, Caiyu / Sun, Yuting / Yang, Hongqiang / Zhou, Shuang / Fang, Bangjiang

    Phytomedicine : international journal of phytotherapy and phytopharmacology

    2023  Volume 111, Page(s) 154665

    Abstract: Background: Lianhua Qingwen Granules or Capsules (LHQW) has accumulated much research evidence ...

    Abstract Background: Lianhua Qingwen Granules or Capsules (LHQW) has accumulated much research evidence in the fight against the coronavirus disease 2019 (COVID-19) epidemic. However, there are still few data on its efficacy and safety in children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
    Purpose: To evaluate the efficacy and safety of LHQW in children with SARS-CoV-2 Omicron infection.
    Methods: We conducted a single-center, propensity-score matched retrospective cohort study of children with SARS-CoV-2 Omicron infection in Shanghai New International Expo Center mobile cabin hospital between April 1st and June 1st, 2022. Eligible patients received either LHQW granules/capsules plus supportive care (LHQW group) or supportive care alone (control group). The primary outcome was the negative conversion time of nucleic acid. Secondary outcomes included the negative conversion rate of nucleic acid, the length of hospital stay, clinical disease progression, and cycle threshold [Ct] values for SARS-CoV-2 open reading frame [ORF1ab] or nucleocapsid [N] genes.
    Results: Overall, 2808 patients were enrolled, and 346 patients in each group were included in the analysis. Among the propensity-score matched groups, LHQW treatment was associated with an accelerated negative conversion time of nucleic acid (median: 5 d vs. 6 d, Hazard ratio: 1.25, 95% CI: 1.08 - 1.46, Log-rank p < 0.001), a higher negative conversion rate of nucleic acid (Day 2 - 6: 2.9% vs. 0.6%, p = 0.036; 29.8% vs. 5.5%, p < 0.001; 42.5% vs. 24.3%, p < 0.001; 51.4% vs. 31.5%, p < 0.001; 63.3% vs. 55.2%, p = 0.030), shorter hospital stay (median: 10 d vs. 11 d, Hazard ratio: 1.50, 95% CI: 1.29 - 1.74, Log-rank p < 0.001), and lower rates of asymptomatic infection progressing to mild (37.9% vs. 46.5%, p = 0.021).
    Conclusion: Our study suggested that LHQW treatment was associated with faster clinical recovery in children with SARS-CoV-2 Omicron infection.
    MeSH term(s) Humans ; Child ; COVID-19 ; SARS-CoV-2 ; Capsules ; Propensity Score ; Retrospective Studies ; China ; Nucleic Acids
    Chemical Substances Capsules ; Nucleic Acids
    Language English
    Publishing date 2023-01-11
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1205240-1
    ISSN 1618-095X ; 0944-7113
    ISSN (online) 1618-095X
    ISSN 0944-7113
    DOI 10.1016/j.phymed.2023.154665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19).

    Zhuang, Jieqin / Dai, Xingzhen / Wu, Qihua / Cai, Hairong / Fu, Xue / Zhang, Weizhang / Chen, Bojun

    Complementary therapies in medicine

    2021  Volume 60, Page(s) 102754

    Abstract: ... on the treatment of COVID-19. As one of the drugs recommended in Chinese guidelines, Lianhua Qingwen Granules or ...

    Abstract Background: Traditional Chinese medicine (TCM) has been proven to played a great important role on the treatment of COVID-19. As one of the drugs recommended in Chinese guidelines, Lianhua Qingwen Granules or Capsules (LQ) are widely used.This systematic review and meta-analysis amis to evaluate the clinical efficacy of LQ on the treatment of COVID-19.
    Methods: Seven databases (PubMed, EMBASE, CENTRAL, CNKI, VIP, CBM and Wanfang) were searched to include all appropriate clinical trials that explore the efficacy of LQ on the treatment of COVID-19.
    Result: A total of 3 trials including 245 COVID-19 patients were eventually enrolled.Compared with the control group,the LQ group showed great significant difference on reducing the rate of clinical change to severe or critical condition[RR = 0.38, 95 %CI (0.17,0.85), P < 0.05]and the fever time (SMD =-0.57,95 %CI (-0.96,-0.17), P<0.05),as well as the significant improvement on the disappearance rate of the clinical symptoms: fever [RR = 1.36,95 %CI (1.14,1.61), P < 0.05],cough[RR = 1.99,95 %CI (1.39,2.86), P < 0.05],fatigue[RR = 1.52,95 %CI (1.15,2.01), P < 0.05] and anhelation [RR = 4.18,95 %CI (1.99,8.81), P < 0.05], but no significance on expectoration[RR = 2.46,95 %CI (0.81,7.51), P < 0.05].
    Conclusion: The clinical application of LQ on the treatment of COVID-19 has significant efficacy in improving clinical symptoms and reducing the rate of clinical change to severe or critical condition. Nevertheless, due to the limited quantity and quality of the included studies, more and higher quality trials with more observational indicators are expected to be published.
    MeSH term(s) COVID-19/therapy ; China/epidemiology ; Clinical Trials as Topic ; Drugs, Chinese Herbal/therapeutic use ; Humans ; Medicine, Chinese Traditional ; SARS-CoV-2
    Chemical Substances Drugs, Chinese Herbal ; lianhuaqingwen
    Language English
    Publishing date 2021-06-19
    Publishing country Scotland
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 1155895-7
    ISSN 1873-6963 ; 0965-2299
    ISSN (online) 1873-6963
    ISSN 0965-2299
    DOI 10.1016/j.ctim.2021.102754
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Shiwei Qingwen decoction regulates TLR4/NF-κB signaling pathway and NLRP3 inflammasome to reduce inflammatory response in lipopolysaccharide-induced acute lung injury.

    Zhang, Qian / Yang, Chengxiong / Ma, Shangzhi / Guo, Shuyun / Hu, Xiaodi / Zhou, Zhongshi / Liu, Yanju / Zhang, Xiuqiao / Jiang, Ruixue / Zhang, Zhihua / Wen, Li

    Journal of ethnopharmacology

    2023  Volume 313, Page(s) 116615

    Abstract: Ethnopharmacological relevance: Shiwei Qingwen decoction (SWQ), a Chinese herbal formula based ...

    Abstract Ethnopharmacological relevance: Shiwei Qingwen decoction (SWQ), a Chinese herbal formula based on the classic traditional Chinese medicine prescription Yu Ping Feng San, has shown efficacy in preventing and treating early pneumonia with good clinical outcomes. However, its underlying mechanism is yet unclear.
    Aim of the study: To clarify the preventive and therapeutic effects of SWQ on lipopolysaccharide (LPS)-induced acute lung injury (ALI) and explore the underlying mechanism by which SWQ influences pneumonia.
    Materials and methods: First, the chemical composition of SWQ was preliminarily determined by high performance liquid chromatography (HPLC), and the impact of SWQ (3.27, 6.55, and 13.1 g/kg) was assessed in the LPS-induced ALI rat model. Next, its inflammatory pathway was determined via network pharmacology. Finally, the molecular mechanism of SWQ was validated using a rat ALI model and a THP-1 cell inflammation model.
    Results: HPLC identified chlorogenic acid, prime-O-glucosylcimifugin, calycosin, and 5-O-methylaminoside in the chemical profile of SWQ. In the ALI model, SWQ alleviated ALI by reducing lung wet/dry weight ratio (W/D) and preventing histopathological damage to the lungs. At the same time, SWQ decreased penetration of inflammatory mediators by upregulating AQP1 and AQP5 and endothelial nitric oxide synthase (eNOS). Pretreatment with SWQ downregulated white blood cells and neutrophils count in BALF and suppressed LPS-induced expression levels of MPO, NE, and pro-inflammatory factors (TNF-α, IL-1β, IL-6, and iNOS). Network pharmacology showed that SWQ was associated with TLR4/NF-κB inflammation pathway. Moreover, pretreatment with SWQ reduced the expression level of TLR4/NF-κB signaling pathway-associated proteins (TLR4, Myd88, p-IκB, and p-p65) and NLRP3 inflammasome (NLRP3, ASC, caspase-1, and cleaved-IL-1β) in vivo and vitro.
    Conclusions: The present study demonstrates that SWQ can reduce inflammation in ALI by inhibiting TLR4/NF-κB and NLRP3 inflammasome activation.
    MeSH term(s) Rats ; Animals ; NF-kappa B/metabolism ; Inflammasomes/metabolism ; Lipopolysaccharides/toxicity ; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism ; Toll-Like Receptor 4/metabolism ; Signal Transduction ; Acute Lung Injury/chemically induced ; Acute Lung Injury/drug therapy ; Lung/pathology ; Inflammation/pathology ; Pneumonia
    Chemical Substances NF-kappa B ; Inflammasomes ; Lipopolysaccharides ; NLR Family, Pyrin Domain-Containing 3 Protein ; shiwei ; Toll-Like Receptor 4 ; Tlr4 protein, rat ; Nlrp3 protein, rat
    Language English
    Publishing date 2023-05-09
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2023.116615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis.

    Hu, Caiyun / He, Bin / Gong, Fengfeng / Liang, Mingming / Zhao, Dongdong / Zhang, Guoliang

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 764774

    Abstract: Objectives: ...

    Abstract Objectives:
    Language English
    Publishing date 2022-01-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.764774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top